
@article{ WOS:000892356700006,
Author = {Yamanashi, Takehiko and Anderson, Zoe-Ella E. M. and Modukuri, Manisha
   and Chang, Gloria and Tran, Tammy and Marra, Pedro S. and Wahba, Nadia
   E. and Crutchley, Kaitlyn J. and Sullivan, Eleanor J. and Jellison,
   Sydney S. and Comp, Katie R. and Akers, Cade C. and Meyer, Alissa A. and
   Lee, Sangil and Iwata, Masaaki and Cho, Hyunkeun R. and Shinozaki, Eri
   and Shinozaki, Gen},
Title = {The potential benefit of metformin to reduce delirium risk and
   mortality: a retrospective cohort study},
Journal = {AGING-US},
Year = {2022},
Volume = {14},
Number = {22},
Pages = {8927-8943},
Month = {NOV 30},
Abstract = {Purpose: Metformin has been reported to improve age-related disorders,
   including dementia, and to lower mortality. This study was conducted to
   investigate whether metformin use lower delirium risk, as well as
   longterm mortality.Methods: In this retrospective cohort study,
   previously recruited 1,404 subjects were analyzed. The relationship
   between metformin use and delirium, and the relationship between
   metformin use and 3-year mortality were investigated.Main findings: 242
   subjects were categorized into a type 2 diabetes mellitus
   (DM)-without-metformin group, and 264 subjects were categorized into a
   DM-with-metformin group. Prevalence of delirium was 36.0\% in the
   DM-without-metformin group, and 29.2\% in the DM-with-metformin group. A
   history of metformin use reduced the risk of delirium in patients with
   DM (OR, 0.50 {[}95\% CI, 0.32 to 0.79]) after controlling for
   confounding factors. The 3-year mortality in the DM-without-metformin
   group (survival rate, 0.595 {[}95\% CI, 0.512 to 0.669]) was higher than
   in the DM-with-metformin group (survival rate, 0.695 {[}95\% CI, 0.604
   to 0.770]) (p=0.035). A history of metformin use decreased the risk of
   3-year mortality after adjustment for confounding factors (HR, 0.69
   {[}95\% CI, 0.48 to 0.98]).Conclusions: Metformin use may lower the risk
   of delirium and mortality in DM patients.},
Publisher = {IMPACT JOURNALS LLC},
Address = {6666 E QUAKER ST, STE 1, ORCHARD PARK, NY 14127 USA},
Type = {Article},
Language = {English},
Affiliation = {Shinozaki, G (Corresponding Author), Stanford Univ, Dept Psychiat \& Behav Sci, Sch Med, Palo Alto, CA 94305 USA.
   Shinozaki, G (Corresponding Author), Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.
   Yamanashi, Takehiko; Shinozaki, Gen, Stanford Univ, Dept Psychiat \& Behav Sci, Sch Med, Palo Alto, CA 94305 USA.
   Yamanashi, Takehiko; Anderson, Zoe-Ella E. M.; Modukuri, Manisha; Chang, Gloria; Tran, Tammy; Marra, Pedro S.; Wahba, Nadia E.; Crutchley, Kaitlyn J.; Sullivan, Eleanor J.; Jellison, Sydney S.; Comp, Katie R.; Akers, Cade C.; Meyer, Alissa A.; Shinozaki, Gen, Univ Iowa, Dept Psychiat, Carver Coll Med, Iowa City, IA 52242 USA.
   Yamanashi, Takehiko; Iwata, Masaaki, Tottori Univ, Dept Neuropsychiat, Fac Med, Yonago, Tottori, Japan.
   Lee, Sangil, Univ Iowa, Dept Emergency Med, Carver Coll Med, Iowa City, IA 52242 USA.
   Cho, Hyunkeun R., Univ Iowa, Dept Biostat, Coll Publ Hlth, Iowa City, IA 52242 USA.
   Shinozaki, Eri, Univ Iowa, Dept Internal Med, Carver Coll Med, Iowa City, IA 52242 USA.},
ISSN = {1945-4589},
Keywords = {delirium; metformin; diabetes mellitus; mortality; aging},
Keywords-Plus = {DNA METHYLATION; SULFONYLUREA MONOTHERAPY; COGNITIVE IMPAIRMENT;
   CANCER-MORTALITY; TYPE-2; DEMENTIA; VALIDATION; PREVENTION; AGE},
Research-Areas = {Cell Biology; Geriatrics \& Gerontology},
Web-of-Science-Categories  = {Cell Biology; Geriatrics \& Gerontology},
Author-Email = {gens@stanford.edu},
Affiliations = {Stanford University; University of Iowa; Tottori University; University
   of Iowa; University of Iowa; University of Iowa},
ResearcherID-Numbers = {Marra, Pedro/JZD-4175-2024
   Shinozaki, Gen/O-1281-2017
   },
ORCID-Numbers = {Shinozaki, Gen/0000-0001-6129-2789
   Marra, Pedro/0000-0001-7171-2169
   Lee, Sangil/0000-0001-8529-4500
   Crutchley, Kaitlyn Johnelle/0000-0002-8565-8033},
Cited-References = {Amidei CB, 2021, JAMA-J AM MED ASSOC, V325, P1640, DOI 10.1001/jama.2021.4001.
   Aroda VR, 2016, J CLIN ENDOCR METAB, V101, P1754, DOI 10.1210/jc.2015-3754.
   Association A.P., 2013, Diagnostic and statistical manual of mental disorders, DOI DOI 10.1176/APPI.BOOKS.9780890425596.744053.
   Bannister CA, 2014, DIABETES OBES METAB, V16, P1165, DOI 10.1111/dom.12354.
   Barzilai N, 2016, CELL METAB, V23, P1060, DOI 10.1016/j.cmet.2016.05.011.
   Bo S, 2012, DIABETES OBES METAB, V14, P23, DOI 10.1111/j.1463-1326.2011.01480.x.
   Cameron AR, 2016, CIRC RES, V119, P652, DOI 10.1161/CIRCRESAHA.116.308445.
   Chen YY, 2021, AGEING RES REV, V65, DOI 10.1016/j.arr.2020.101205.
   Cheng G, 2012, INTERN MED J, V42, P484, DOI 10.1111/j.1445-5994.2012.02758.x.
   Cho EH, 2020, MEDICINE, V99, DOI 10.1097/MD.0000000000021236.
   Crane PK, 2013, NEW ENGL J MED, V369, P540, DOI {[}10.1056/NEJMoa1215740, 10.1056/NEJMc1311765].
   Ely EW, 2001, JAMA-J AM MED ASSOC, V286, P2703, DOI 10.1001/jama.286.21.2703.
   Fang EF, 2020, AGEING RES REV, V64, DOI 10.1016/j.arr.2020.101174.
   Farr SA, 2019, J ALZHEIMERS DIS, V68, P1699, DOI 10.3233/JAD-181240.
   Feng XF, 2020, AGING-US, V12, P1087, DOI 10.18632/aging.102635.
   Fong TG, 2009, NAT REV NEUROL, V5, P210, DOI 10.1038/nrneurol.2009.24.
   Girard TD, 2018, NEW ENGL J MED, V379, P2506, DOI 10.1056/NEJMoa1808217.
   Glossmann HH, 2019, GERONTOLOGY, V65, P581, DOI 10.1159/000502257.
   Govindpani K, 2019, J CLIN MED, V8, DOI 10.3390/jcm8050651.
   Grover S, 2018, INDIAN J PSYCHIAT, V60, P329, DOI 10.4103/0019-5545.224473.
   Inouye SK, 2014, LANCET, V383, P911, DOI 10.1016/S0140-6736(13)60688-1.
   Inouye SK, 2006, NEW ENGL J MED, V354, P1157, DOI 10.1056/NEJMra052321.
   Inouye SK, 2005, J AM GERIATR SOC, V53, P312, DOI 10.1111/j.1532-5415.2005.53120.x.
   Johnson JA, 2002, DIABETES CARE, V25, P2244, DOI 10.2337/diacare.25.12.2244.
   Kanda Y, 2013, BONE MARROW TRANSPL, V48, P452, DOI 10.1038/bmt.2012.244.
   Kulkarni AS, 2020, CELL METAB, V32, P15, DOI 10.1016/j.cmet.2020.04.001.
   Landman GWD, 2010, DIABETES CARE, V33, P322, DOI 10.2337/dc09-1380.
   Maldonado JR, 2018, INT J GERIATR PSYCH, V33, P1428, DOI 10.1002/gps.4823.
   McCusker J, 2002, ARCH INTERN MED, V162, P457, DOI 10.1001/archinte.162.4.457.
   Nikooie R, 2019, ANN INTERN MED, V171, P485, DOI 10.7326/M19-1860.
   Oh ES, 2019, ANN INTERN MED, V171, P474, DOI 10.7326/M19-1859.
   Oliveira WH, 2016, BRAIN RES, V1644, P149, DOI 10.1016/j.brainres.2016.05.013.
   Orkaby AR, 2017, NEUROLOGY, V89, P1877, DOI {[}10.1212/wnl.0000000000004586, 10.1212/WNL.0000000000004586].
   Pandharipande PP, 2013, NEW ENGL J MED, V369, P1306, DOI 10.1056/NEJMoa1301372.
   Partridge L, 2018, NATURE, V561, P45, DOI 10.1038/s41586-018-0457-8.
   Ping F, 2020, BMJ OPEN DIAB RES CA, V8, DOI 10.1136/bmjdrc-2020-001370.
   Saito T, 2021, BRAIN COMMUN, V3, DOI 10.1093/braincomms/fcab037.
   Saito T, 2020, NEUROBIOL AGING, V94, P227, DOI 10.1016/j.neurobiolaging.2020.06.003.
   Saito T, 2020, J PSYCHIATR RES, V129, P61, DOI 10.1016/j.jpsychires.2020.06.005.
   Scherrer JF, 2019, ANN FAM MED, V17, P352, DOI 10.1370/afm.2415.
   Schuurmans Marieke J, 2003, Res Theory Nurs Pract, V17, P31, DOI 10.1891/088971803780956425.
   Shao SC, 2021, AGE AGEING, V50, P1445, DOI 10.1093/ageing/afab103.
   Shinozaki G, 2019, J CLIN PSYCHIAT, V80, DOI 10.4088/JCP.19m12749.
   Shinozaki G, 2018, PSYCHIAT CLIN NEUROS, V72, P856, DOI 10.1111/pcn.12783.
   Trzepacz PT, 2001, J NEUROPSYCH CLIN N, V13, P229, DOI 10.1176/appi.neuropsych.13.2.229.
   Turner RC, 1998, LANCET, V352, P854, DOI 10.1016/s0140-6736(98)07037-8.
   van Keulen K, 2018, CRIT CARE MED, V46, P1444, DOI 10.1097/CCM.0000000000003285.
   Wang CP, 2017, J DIABETES COMPLICAT, V31, P679, DOI {[}10.1016/jjdiacomp.2017.01.013, 10.1016/j.jdiacomp.2017.01.013].
   Wium-Andersen IK, 2019, EUR J ENDOCRINOL, V181, P499, DOI 10.1530/EJE-19-0259.
   Wong A, 2019, PSYCHOL DISORDERS RE, DOI {[}10.31487/j.PDR.2019.03.01, DOI 10.31487/J.PDR.2019.03.01].
   Yamanashi T, 2022, BRIT J PSYCHIAT, V220, P322, DOI 10.1192/bjp.2021.101.
   Yamanashi T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-021-93588-9.
   Yamanashi T, 2021, NEUROBIOL AGING, V105, P310, DOI 10.1016/j.neurobiolaging.2021.05.005.
   Yamanashi T, 2021, SCI REP-UK, V11, DOI 10.1038/s41598-020-79391-y.
   Yamanashi T, 2021, J AM GERIATR SOC, V69, P140, DOI 10.1111/jgs.16815.
   Yang F, 2019, INT J BIOL SCI, V15, P1010, DOI 10.7150/ijbs.29680.
   Zhou ZE, 2016, J DIABETES RES, V2016, DOI 10.1155/2016/4847812.},
Number-of-Cited-References = {57},
Times-Cited = {4},
Usage-Count-Last-180-days = {0},
Usage-Count-Since-2013 = {3},
Journal-ISO = {Aging-US},
Doc-Delivery-Number = {6R5QD},
Web-of-Science-Index = {Science Citation Index Expanded (SCI-EXPANDED)},
Unique-ID = {WOS:000892356700006},
OA = {gold, Green Published},
DA = {2024-09-07},
}
